Oppenheimer Asset Management Inc. Has $6.82 Million Stock Holdings in Haleon plc (NYSE:HLN)

Oppenheimer Asset Management Inc. increased its position in shares of Haleon plc (NYSE:HLN - Free Report) by 18.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 825,675 shares of the company's stock after purchasing an additional 129,287 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Haleon were worth $6,820,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Cultivar Capital Inc. bought a new stake in shares of Haleon in the 2nd quarter valued at approximately $40,000. Allspring Global Investments Holdings LLC bought a new position in shares of Haleon during the first quarter valued at $43,000. GAMMA Investing LLC boosted its stake in shares of Haleon by 151.3% in the 1st quarter. GAMMA Investing LLC now owns 6,106 shares of the company's stock valued at $52,000 after purchasing an additional 3,676 shares in the last quarter. Pinnacle Bancorp Inc. grew its holdings in shares of Haleon by 29.8% in the 1st quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company's stock worth $53,000 after purchasing an additional 1,421 shares during the last quarter. Finally, Hexagon Capital Partners LLC increased its position in shares of Haleon by 66.6% during the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company's stock worth $55,000 after purchasing an additional 2,677 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HLN shares. Berenberg Bank began coverage on shares of Haleon in a report on Tuesday, August 6th. They set a "buy" rating for the company. The Goldman Sachs Group cut Haleon from a "buy" rating to a "neutral" rating in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy".

Haleon Price Performance

Shares of HLN traded up $0.12 during mid-day trading on Monday, hitting $10.63. 4,575,324 shares of the company traded hands, compared to its average volume of 4,950,894. The stock has a market capitalization of $48.54 billion, a price-to-earnings ratio of 35.37, a PEG ratio of 3.10 and a beta of 0.26. Haleon plc has a one year low of $7.70 and a one year high of $10.65. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $9.58 and a 200 day moving average of $8.80.

Haleon (NYSE:HLN - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The business had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same period last year, the firm earned $0.08 earnings per share. As a group, equities analysts expect that Haleon plc will post 0.46 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Thursday, September 19th. Stockholders of record on Friday, August 16th will be paid a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, August 16th. Haleon's dividend payout ratio (DPR) is currently 33.33%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.